CASP1 and congenital adrenal hyperplasia: Acombination therapy using melaxen led to a more significant decrease in thedevelopment of apoptotic processes in CAH patients, as evidenced by a moresignificant decrease in the activity of caspase-1 and caspase-3, and the DNAfragmentation degree, than that in patients who received the conventionaltherapy.